PE20040455A1 - Compuestos moduladores selectivos de receptores opiaceos - Google Patents
Compuestos moduladores selectivos de receptores opiaceosInfo
- Publication number
- PE20040455A1 PE20040455A1 PE2003000457A PE2003000457A PE20040455A1 PE 20040455 A1 PE20040455 A1 PE 20040455A1 PE 2003000457 A PE2003000457 A PE 2003000457A PE 2003000457 A PE2003000457 A PE 2003000457A PE 20040455 A1 PE20040455 A1 PE 20040455A1
- Authority
- PE
- Peru
- Prior art keywords
- opiace
- modulator compounds
- compounds
- selective modulator
- receiver
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- UPNUIXSCZBYVBB-JVFUWBCBSA-N alvimopan Chemical compound C([C@@H](CN1C[C@@H]([C@](CC1)(C)C=1C=C(O)C=CC=1)C)C(=O)NCC(O)=O)C1=CC=CC=C1 UPNUIXSCZBYVBB-JVFUWBCBSA-N 0.000 abstract 1
- 229960004516 alvimopan Drugs 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- JHLHNYVMZCADTC-LOSJGSFVSA-N asimadoline Chemical compound C([C@@H](N(C)C(=O)C(C=1C=CC=CC=1)C=1C=CC=CC=1)C=1C=CC=CC=1)N1CC[C@H](O)C1 JHLHNYVMZCADTC-LOSJGSFVSA-N 0.000 abstract 1
- 229950002202 asimadoline Drugs 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000001079 digestive effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- MVKIWCDXKCUDEH-QFIPXVFZSA-N fedotozine Chemical compound C([C@](CC)(N(C)C)C=1C=CC=CC=1)OCC1=CC(OC)=C(OC)C(OC)=C1 MVKIWCDXKCUDEH-QFIPXVFZSA-N 0.000 abstract 1
- 229950008449 fedotozine Drugs 0.000 abstract 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001571 loperamide Drugs 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02011047 | 2002-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040455A1 true PE20040455A1 (es) | 2004-08-07 |
Family
ID=29433078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000457A PE20040455A1 (es) | 2002-05-17 | 2003-05-13 | Compuestos moduladores selectivos de receptores opiaceos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050176746A1 (enExample) |
| EP (2) | EP2074997A1 (enExample) |
| JP (1) | JP2005531557A (enExample) |
| KR (1) | KR101108014B1 (enExample) |
| CN (2) | CN101310723A (enExample) |
| AR (1) | AR040028A1 (enExample) |
| AT (1) | ATE429226T1 (enExample) |
| AU (1) | AU2003242527B2 (enExample) |
| BR (1) | BR0309969A (enExample) |
| CA (1) | CA2486000A1 (enExample) |
| DE (1) | DE60327315D1 (enExample) |
| DK (1) | DK1505974T3 (enExample) |
| ES (1) | ES2325782T3 (enExample) |
| MX (1) | MXPA04011333A (enExample) |
| PE (1) | PE20040455A1 (enExample) |
| PL (1) | PL371596A1 (enExample) |
| RU (1) | RU2336871C2 (enExample) |
| TW (1) | TWI314053B (enExample) |
| WO (1) | WO2003097051A2 (enExample) |
| ZA (1) | ZA200410160B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10259245A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivate des Asimadolins mit kovalent gebundenen Säuren |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| DE602004028678D1 (de) | 2003-01-28 | 2010-09-23 | Ironwood Pharmaceuticals Inc | Zusammensetzungen zur Behandlung von Magen-Darm-Störungen |
| MXPA05011557A (es) | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
| EP1870096A3 (en) * | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| WO2005046687A1 (en) * | 2003-10-30 | 2005-05-26 | Tioga Pharmaceuticals, Inc. | Use of selective opiate receptor modulators in the treatment of neuropathy |
| EP2292220A3 (en) | 2005-11-22 | 2012-01-04 | Orexigen Therapeutics, Inc. | Composition and methods for increasing insulin sensitivity |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
| PT2136801E (pt) * | 2007-03-30 | 2012-12-06 | Tioga Pharmaceuticals Inc | Agonistas kappa-opiáceos para o tratamento do síndrome do intestino irritável com predomínio de diarreia ou alternância |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US20110144145A1 (en) | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| CA2930674A1 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| CA2994066A1 (en) | 2008-12-03 | 2010-06-10 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| KR20220042487A (ko) | 2008-12-31 | 2022-04-05 | 알데릭스, 인코포레이티드 | 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법 |
| RU2413512C1 (ru) * | 2009-07-29 | 2011-03-10 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" | Средство, обладающее каппа-опиоидной агонистической активностью |
| CN102724878A (zh) | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
| WO2012012410A2 (en) * | 2010-07-19 | 2012-01-26 | Dr. Reddy's Laboratories Ltd. | Kappa opioid receptor agonists |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| KR102034748B1 (ko) | 2011-03-01 | 2019-10-21 | 시너지 파마슈티컬즈 인코포레이티드 | 구아닐레이트 사이클라제 c 작용제의 제조 방법 |
| KR20220042241A (ko) | 2012-06-06 | 2022-04-04 | 오렉시젠 세러퓨틱스 인크. | 과체중 및 비만의 치료 방법 |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| JP6392754B2 (ja) | 2012-08-21 | 2018-09-19 | アーデリクス，インコーポレーテッド | 体液貯留又は塩過負荷に関係する疾患及び消化管疾患の治療におけるｎｈｅ仲介の逆輸送を阻害するための化合物並びに方法 |
| US9675587B2 (en) | 2013-03-14 | 2017-06-13 | Allergan Holdings Unlimited Company | Opioid receptor modulator dosage formulations |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| BR112015025805A2 (pt) | 2013-04-12 | 2017-07-25 | Ardelyx Inc | compostos de ligação de nh3 e métodos para inibir o transporte de fosfato |
| EP4424697A3 (en) | 2013-06-05 | 2024-12-25 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| EA023231B1 (ru) * | 2013-07-18 | 2016-05-31 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН) | Применение агониста каппа опиоидных рецепторов периферического действия ici 204,448 для приготовления средств для лечения синдрома отмены никотина |
| US20160250277A1 (en) * | 2013-10-28 | 2016-09-01 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| BR112019013963A2 (pt) | 2017-01-09 | 2020-04-28 | Ardelyx Inc | inibidores de antiporte mediado por nhe |
| WO2018129552A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889860A (en) * | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
| DE4034785A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | 1-(2-arylethyl)-pyrrolidine |
| DE3935371A1 (de) | 1988-12-23 | 1990-07-05 | Merck Patent Gmbh | Stickstoffhaltige ringverbindungen |
| US5389686A (en) * | 1989-02-20 | 1995-02-14 | Jouveinal Sa | Analgesic properties of fedotozine |
| DE4215213A1 (de) | 1992-05-09 | 1993-11-11 | Merck Patent Gmbh | Arylacetamide |
| DE4215231C1 (en) | 1992-05-09 | 1993-05-13 | Dornier Luftfahrt Gmbh, 8031 Wessling, De | Arrangement for mfg. fibre reinforced thermoplastic components - including unit for accommodating component, pressurising unit for assembled component and heating unit |
| DE19523502A1 (de) * | 1995-06-28 | 1997-01-02 | Merck Patent Gmbh | Kappa-Opiatagonisten für entzündliche Darmerkrankungen |
| DE19531464A1 (de) * | 1995-08-26 | 1997-02-27 | Merck Patent Gmbh | N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid |
| EP1021204B1 (en) * | 1997-09-26 | 2005-12-28 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| US20010051181A1 (en) * | 1997-12-22 | 2001-12-13 | Van Osdol William W. | Novel formulations for the transdermal administration of asimadoline |
| JPH11343244A (ja) * | 1998-03-30 | 1999-12-14 | Taisho Pharmaceut Co Ltd | 経口用組成物 |
| JP2000080047A (ja) * | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
| KR100773776B1 (ko) * | 1998-07-14 | 2007-11-12 | 얀센 파마슈티카 엔.브이. | 신경친화성 성장 인자 |
| EP1033364B1 (en) * | 1999-03-01 | 2005-02-23 | Pfizer Products Inc. | Cyano containing oxamic acids and derivatives as thyroid receptor ligands |
| JP2005508830A (ja) * | 2000-06-19 | 2005-04-07 | エーザイ株式会社 | ピリジン誘導体を用いる方法 |
| GB0015562D0 (en) * | 2000-06-23 | 2000-08-16 | Pfizer Ltd | Heterocycles |
| DE10030893A1 (de) * | 2000-06-23 | 2002-01-03 | Henkel Kgaa | Paraaminophenol-Derivate und deren Verwendung |
| US6262062B1 (en) * | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
| WO2003048113A1 (en) * | 2001-11-30 | 2003-06-12 | Sepracor Inc. | Tramadol analogs and uses thereof |
-
2003
- 2003-04-28 JP JP2004505050A patent/JP2005531557A/ja active Pending
- 2003-04-28 WO PCT/EP2003/004428 patent/WO2003097051A2/en not_active Ceased
- 2003-04-28 KR KR1020047018468A patent/KR101108014B1/ko not_active Expired - Fee Related
- 2003-04-28 PL PL03371596A patent/PL371596A1/xx not_active Application Discontinuation
- 2003-04-28 CN CNA2008101295692A patent/CN101310723A/zh active Pending
- 2003-04-28 US US10/514,887 patent/US20050176746A1/en not_active Abandoned
- 2003-04-28 BR BR0309969-5A patent/BR0309969A/pt not_active Application Discontinuation
- 2003-04-28 RU RU2004137091/15A patent/RU2336871C2/ru not_active IP Right Cessation
- 2003-04-28 ES ES03752716T patent/ES2325782T3/es not_active Expired - Lifetime
- 2003-04-28 AU AU2003242527A patent/AU2003242527B2/en not_active Ceased
- 2003-04-28 DE DE60327315T patent/DE60327315D1/de not_active Expired - Lifetime
- 2003-04-28 DK DK03752716T patent/DK1505974T3/da active
- 2003-04-28 CN CNB038111373A patent/CN100411618C/zh not_active Expired - Fee Related
- 2003-04-28 AT AT03752716T patent/ATE429226T1/de not_active IP Right Cessation
- 2003-04-28 CA CA002486000A patent/CA2486000A1/en not_active Abandoned
- 2003-04-28 MX MXPA04011333A patent/MXPA04011333A/es active IP Right Grant
- 2003-04-28 EP EP09158047A patent/EP2074997A1/en not_active Withdrawn
- 2003-04-28 EP EP03752716A patent/EP1505974B1/en not_active Expired - Lifetime
- 2003-05-12 TW TW092112843A patent/TWI314053B/zh not_active IP Right Cessation
- 2003-05-13 PE PE2003000457A patent/PE20040455A1/es not_active Application Discontinuation
- 2003-05-16 AR ARP030101709A patent/AR040028A1/es unknown
-
2004
- 2004-12-15 ZA ZA2004/10160A patent/ZA200410160B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1079451A1 (zh) | 2006-04-07 |
| AU2003242527B2 (en) | 2008-10-23 |
| EP2074997A1 (en) | 2009-07-01 |
| DK1505974T3 (da) | 2009-08-17 |
| AR040028A1 (es) | 2005-03-09 |
| US20050176746A1 (en) | 2005-08-11 |
| TWI314053B (en) | 2009-09-01 |
| JP2005531557A (ja) | 2005-10-20 |
| CN100411618C (zh) | 2008-08-20 |
| CA2486000A1 (en) | 2003-11-27 |
| MXPA04011333A (es) | 2005-02-14 |
| ATE429226T1 (de) | 2009-05-15 |
| BR0309969A (pt) | 2005-04-26 |
| PL371596A1 (en) | 2005-06-27 |
| AU2003242527A1 (en) | 2003-12-02 |
| ES2325782T3 (es) | 2009-09-17 |
| RU2004137091A (ru) | 2005-09-10 |
| CN1655784A (zh) | 2005-08-17 |
| CN101310723A (zh) | 2008-11-26 |
| EP1505974A2 (en) | 2005-02-16 |
| WO2003097051A2 (en) | 2003-11-27 |
| DE60327315D1 (de) | 2009-06-04 |
| EP1505974B1 (en) | 2009-04-22 |
| KR101108014B1 (ko) | 2012-01-25 |
| RU2336871C2 (ru) | 2008-10-27 |
| TW200307541A (en) | 2003-12-16 |
| KR20050010807A (ko) | 2005-01-28 |
| ZA200410160B (en) | 2005-12-28 |
| WO2003097051A3 (en) | 2004-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040455A1 (es) | Compuestos moduladores selectivos de receptores opiaceos | |
| PA8493701A1 (es) | Compuestos para tratar la obesidad | |
| CL2008003825A1 (es) | Compuestos derivados de 4-pirrolidinbenzonitrilo, moduladores selectivos de receptores de androgeno; composicion farmaceutica; kit farmaceutico; y su uso en el tratamiento de una enfermedad o trastorno seleccionada de piel envejecida, enfermedad de alzheimer, anemia, artritis, gota, arterosclerosis, enfermedad osea, entre otras. | |
| EP2298744A3 (en) | Opioid receptor modulators | |
| LT2006017A (en) | 2-(quinoxalin-5-ylsulfonylamino)-benzamide compounds as cck2 modulators | |
| AR035348A1 (es) | Indoles sustituidos, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la preparacion de medicamentos | |
| EA200600048A1 (ru) | Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором | |
| PA8513801A1 (es) | Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo | |
| TW200612892A (en) | Novel compounds | |
| EP2327709A3 (en) | Modulation of glucagon receptor expression | |
| PA8493801A1 (es) | Moduladores del receptor glucocorticoide | |
| UY27360A1 (es) | Compuestos heterobicíclicos sustituídos con triamida | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| WO2003092580A3 (en) | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | |
| TW200510301A (en) | Novel compounds | |
| TW200510303A (en) | Novel compounds | |
| CL2004000868A1 (es) | Compuestos derivados de acidos carboxilicos, antagonistas del receptor de calcio 8casr); composiciones farmaceuticas que comprenden el compuesto, utiles para el tratamiento de osteoporosis. | |
| NI201100162A (es) | Derivados de indol como antagonistas del receptor crth2 | |
| TW200732296A (en) | Novel compounds | |
| MX2010006388A (es) | Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina. | |
| ECSP088366A (es) | 1,2-diarilimidazoles para uso como moduladores de cb1 | |
| MX2010003948A (es) | N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas. | |
| DE60228561D1 (de) | Immunotherapeutische kombinationen zur behandlung von tumoren, die ganglioside überexprimieren | |
| BRPI0607309A2 (pt) | processos para a preparação de fenilpirazol uréias substituìdas | |
| EA200501868A1 (ru) | ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |